PER 001
Alternative Names: PER-001Latest Information Update: 07 Sep 2023
At a glance
- Originator Perfuse Therapeutics
- Class Eye disorder therapies; Small molecules
- Mechanism of Action Endothelin receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Diabetic retinopathy
- Phase I/II Glaucoma
- Research Dry age-related macular degeneration; Retinal vein occlusion
Most Recent Events
- 03 Aug 2023 Phase-II clinical trials in Diabetic retinopathy in USA (Intravitreous) (NCT06003751)
- 07 Apr 2023 Early research in Dry age-related macular degeneration in USA (Intravitreous) (Perfuse therapeutics pipeline, April 2023)
- 07 Apr 2023 Early research in Retinal vein occlusion in USA (Intravitreous) (Perfuse therapeutics pipeline, April 2023)